Angioedema and acute urticaria in a patient with COVID 19 pneumonia: Favipiravir side effect or COVID-19 cutaneous manifestation

Sevil Alkan Çeviker; Alper Şener; Cihan Yüksel; Taylan Önder; Anıl Akça; Servan Vurucu; Safiye Güçlü

doi:10.33706/jemcr.851107

Case Report

Angioedema and acute urticaria in a patient with COVID 19 pneumonia: Favipiravir side effect or COVID-19 cutaneous manifestation

Year 2021, Volume: 12 Issue: 2, 65 - 67, 11.06.2021

Sevil Alkan Çeviker , Alper Şener , Cihan Yüksel Taylan Önder , Anıl Akça Servan Vurucu , Safiye Güçlü

https://doi.org/10.33706/jemcr.851107

Cited By: 5

Abstract

Coronavirus disease 2019 (COVID-19) has caused thousands of deaths since it was declared as a pandemic and continues to be one of the most followed topics in the world in terms of its course and treatment. Favipiravir is a broad-spectrum anti-viral agent that has been shown to be effective against various Coronaviruses in vitro. However, as with any drug use, side effects may develop with the use of favipravir treatment. We aimed to present a case of angioedema and acute urticaria whom had COVID 19 pneumonia, that we cannot distinguish as a rare side effect due to favipiravir treatment or COVID-19 cutaneous manifestation. According to the available literature, this is the first case reported in our country.

Keywords

COVID-19, Favipiravir, side effect, SARS-CoV-2, Cutaneous manifestations, angioedema, acute urticaria

Project Number

yok

References

1. Khambholja K, Asudani D. Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence. Travel Med Infect Dis. 2020;35:101710. doi: 10.1016/j.tmaid.2020.101710.
2. Wang M, Cao R, zhang L et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269-71.
3. McCreary EK, pogue M, on behalf of the Society of Infectious Diseases pharmacists. COVID-19 Treatment: a review of early and emerging options. OFID . 2020;7:ofaa105.
4. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020. doi: 10.1016/j. eng.2020.03.007
5. Galván Casas C, Català A, Carretero Hernández G, Rodríguez-Jiménez P, Fernández-Nieto D, Rodríguez-Villa Lario A, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71-77. doi: 10.1111/bjd.19163.
6. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34(5):e212-e213. doi: 10.1111/jdv.16387. PMID: 32215952.
7. Marzano AV, Genovese G, Fabbrocini G, et al. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients. J Am Acad Dermatol 2020;83(1):280-5. doi: 10.1016/j.jaad.2020.04.044.
8. Jindal R, Chauhan P. Cutaneous manifestations of coronavirus disease 2019 in 458 confirmed cases: A systematic review. J Family Med Prim Care. 2020;9(9):4563-9. doi: 10.4103/jfmpc.jfmpc_872_20.
9. DiFrancesco MF, Solomon SD, Vaduganathan M. Angioedema in COVID 19. Eur Heart J. 2020;34: 3283–4. doi.org/10.1093/eurheartj/ehaa452
10. Rahimi H, Tehranchinia Z. A Comprehensive Review of Cutaneous Manifestations Associated with COVID-19. Biomed Res Int. 2020;2020:1236520. doi: 10.1155/2020/1236520.
11. Hassan K. Urticaria and angioedema as a prodromal cutaneous manifestation of SARS-CoV-2 (COVID-19) infection. BMJ Case Rep. 2020;13(7):e236981. doi: 10.1136/bcr-2020-236981.
12. Abasaeed Elhag SA, Ibrahim H, Abdelhadi S. Angioedema and urticaria in a COVID-19 patient: A case report and review of the literature. JAAD Case Rep. 2020;6(10):1091-1094. doi: 10.1016/j.jdcr.2020.07.042.
13. Adeliño R, Andrés-Cordón JF, Aracelis De La Cruz Martínez C. Acute urticaria with angioedema in the setting of coronavirus disease 2019. J Allergy Clin Immunol Pract. 2020;8(7):2386-2387. doi: 10.1016/j.jaip.2020.04.061.
14. Najafzadeh M, Shahzad F, Ghaderi N, Ansari K, Jacob B, Wright A. Urticaria (angioedema) and COVID-19 infection. J Eur Acad Dermatol Venereol. 2020;34(10):e568-e570. doi: 10.1111/jdv.16721.
15. Cohen AJ, DiFrancesco MF, Solomon SD, Vaduganathan M. Angioedema in COVID-19. Eur Heart J. 2020;41(34):3283-3284. doi: 10.1093/eurheartj/ehaa452.
16. Grewal E, Sutarjono B, Mohammed I. Angioedema, ACE inhibitor and COVID-19. BMJ Case Rep. 2020;13(9):e237888. doi: 10.1136/bcr-2020-237888.
17. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34:e212–e213

Year 2021, Volume: 12 Issue: 2, 65 - 67, 11.06.2021

Sevil Alkan Çeviker , Alper Şener , Cihan Yüksel Taylan Önder , Anıl Akça Servan Vurucu , Safiye Güçlü

https://doi.org/10.33706/jemcr.851107

Cited By: 5

Abstract

Supporting Institution

yok

Project Number

yok

References

1. Khambholja K, Asudani D. Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence. Travel Med Infect Dis. 2020;35:101710. doi: 10.1016/j.tmaid.2020.101710.
2. Wang M, Cao R, zhang L et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269-71.
3. McCreary EK, pogue M, on behalf of the Society of Infectious Diseases pharmacists. COVID-19 Treatment: a review of early and emerging options. OFID . 2020;7:ofaa105.
4. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020. doi: 10.1016/j. eng.2020.03.007
5. Galván Casas C, Català A, Carretero Hernández G, Rodríguez-Jiménez P, Fernández-Nieto D, Rodríguez-Villa Lario A, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71-77. doi: 10.1111/bjd.19163.
6. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34(5):e212-e213. doi: 10.1111/jdv.16387. PMID: 32215952.
7. Marzano AV, Genovese G, Fabbrocini G, et al. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients. J Am Acad Dermatol 2020;83(1):280-5. doi: 10.1016/j.jaad.2020.04.044.
8. Jindal R, Chauhan P. Cutaneous manifestations of coronavirus disease 2019 in 458 confirmed cases: A systematic review. J Family Med Prim Care. 2020;9(9):4563-9. doi: 10.4103/jfmpc.jfmpc_872_20.
9. DiFrancesco MF, Solomon SD, Vaduganathan M. Angioedema in COVID 19. Eur Heart J. 2020;34: 3283–4. doi.org/10.1093/eurheartj/ehaa452
10. Rahimi H, Tehranchinia Z. A Comprehensive Review of Cutaneous Manifestations Associated with COVID-19. Biomed Res Int. 2020;2020:1236520. doi: 10.1155/2020/1236520.
11. Hassan K. Urticaria and angioedema as a prodromal cutaneous manifestation of SARS-CoV-2 (COVID-19) infection. BMJ Case Rep. 2020;13(7):e236981. doi: 10.1136/bcr-2020-236981.
12. Abasaeed Elhag SA, Ibrahim H, Abdelhadi S. Angioedema and urticaria in a COVID-19 patient: A case report and review of the literature. JAAD Case Rep. 2020;6(10):1091-1094. doi: 10.1016/j.jdcr.2020.07.042.
13. Adeliño R, Andrés-Cordón JF, Aracelis De La Cruz Martínez C. Acute urticaria with angioedema in the setting of coronavirus disease 2019. J Allergy Clin Immunol Pract. 2020;8(7):2386-2387. doi: 10.1016/j.jaip.2020.04.061.
14. Najafzadeh M, Shahzad F, Ghaderi N, Ansari K, Jacob B, Wright A. Urticaria (angioedema) and COVID-19 infection. J Eur Acad Dermatol Venereol. 2020;34(10):e568-e570. doi: 10.1111/jdv.16721.
15. Cohen AJ, DiFrancesco MF, Solomon SD, Vaduganathan M. Angioedema in COVID-19. Eur Heart J. 2020;41(34):3283-3284. doi: 10.1093/eurheartj/ehaa452.
16. Grewal E, Sutarjono B, Mohammed I. Angioedema, ACE inhibitor and COVID-19. BMJ Case Rep. 2020;13(9):e237888. doi: 10.1136/bcr-2020-237888.
17. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34:e212–e213

There are 17 citations in total.

Details

Primary Language	English
Subjects	Clinical Sciences
Journal Section	Case Report
Authors	Sevil Alkan Çeviker 0000-0003-1944-2477 Alper Şener 0000-0003-2774-8601 Cihan Yüksel This is me 0000-0002-6861-9163 Taylan Önder 0000-0003-0684-4047 Anıl Akça This is me 0000-0001-5029-9838 Servan Vurucu 0000-0001-8623-7639 Safiye Güçlü This is me 0000-0002-8403-8430
Project Number	yok
Publication Date	June 11, 2021
Submission Date	December 31, 2020
Published in Issue	Year 2021 Volume: 12 Issue: 2

Cite

APA	Alkan Çeviker, S., Şener, A., Yüksel, C., Önder, T., et al. (2021). Angioedema and acute urticaria in a patient with COVID 19 pneumonia: Favipiravir side effect or COVID-19 cutaneous manifestation. Journal of Emergency Medicine Case Reports, 12(2), 65-67. https://doi.org/10.33706/jemcr.851107
AMA	Alkan Çeviker S, Şener A, Yüksel C, Önder T, Akça A, Vurucu S, Güçlü S. Angioedema and acute urticaria in a patient with COVID 19 pneumonia: Favipiravir side effect or COVID-19 cutaneous manifestation. Journal of Emergency Medicine Case Reports. June 2021;12(2):65-67. doi:10.33706/jemcr.851107
Chicago	Alkan Çeviker, Sevil, Alper Şener, Cihan Yüksel, Taylan Önder, Anıl Akça, Servan Vurucu, and Safiye Güçlü. “Angioedema and Acute Urticaria in a Patient With COVID 19 Pneumonia: Favipiravir Side Effect or COVID-19 Cutaneous Manifestation”. Journal of Emergency Medicine Case Reports 12, no. 2 (June 2021): 65-67. https://doi.org/10.33706/jemcr.851107.
EndNote	Alkan Çeviker S, Şener A, Yüksel C, Önder T, Akça A, Vurucu S, Güçlü S (June 1, 2021) Angioedema and acute urticaria in a patient with COVID 19 pneumonia: Favipiravir side effect or COVID-19 cutaneous manifestation. Journal of Emergency Medicine Case Reports 12 2 65–67.
IEEE	S. Alkan Çeviker, A. Şener, C. Yüksel, T. Önder, A. Akça, S. Vurucu, and S. Güçlü, “Angioedema and acute urticaria in a patient with COVID 19 pneumonia: Favipiravir side effect or COVID-19 cutaneous manifestation”, Journal of Emergency Medicine Case Reports, vol. 12, no. 2, pp. 65–67, 2021, doi: 10.33706/jemcr.851107.
ISNAD	Alkan Çeviker, Sevil et al. “Angioedema and Acute Urticaria in a Patient With COVID 19 Pneumonia: Favipiravir Side Effect or COVID-19 Cutaneous Manifestation”. Journal of Emergency Medicine Case Reports 12/2 (June 2021), 65-67. https://doi.org/10.33706/jemcr.851107.
JAMA	Alkan Çeviker S, Şener A, Yüksel C, Önder T, Akça A, Vurucu S, Güçlü S. Angioedema and acute urticaria in a patient with COVID 19 pneumonia: Favipiravir side effect or COVID-19 cutaneous manifestation. Journal of Emergency Medicine Case Reports. 2021;12:65–67.
MLA	Alkan Çeviker, Sevil et al. “Angioedema and Acute Urticaria in a Patient With COVID 19 Pneumonia: Favipiravir Side Effect or COVID-19 Cutaneous Manifestation”. Journal of Emergency Medicine Case Reports, vol. 12, no. 2, 2021, pp. 65-67, doi:10.33706/jemcr.851107.
Vancouver	Alkan Çeviker S, Şener A, Yüksel C, Önder T, Akça A, Vurucu S, Güçlü S. Angioedema and acute urticaria in a patient with COVID 19 pneumonia: Favipiravir side effect or COVID-19 cutaneous manifestation. Journal of Emergency Medicine Case Reports. 2021;12(2):65-7.